However, in this case, pan-cancer analyses revealed that Siglec15 exerted no immunosuppressive effect in the majority of cancers, including lung adenocarcinoma, lung squamous cell carcinoma, BRCA, head and neck squamous cell carcinoma, and OV, which were enrolled in a phase II clinical trial of Siglec15 inhibitor. Here, SIGLEC15 is linked to head and neck squamous cell carcinoma.